



ASX ANNOUNCEMENT

Lumos quarterly update video interview with CEO, Doug Ward

MELBOURNE, Australia (2 May 2024) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care diagnostic technologies, is pleased to share a video interview where CEO and Managing Director, Doug Ward discusses the highlights of the Q3 FY24 quarterly report and operational progress.

Key highlights include:

- An overview of the factors which led to Lumos achieving its first positive quarter of cashflow generation
- The planned accounting treatment for payments recognised under the recently reported agreements with Hologic (ASX announcements: 11 January 2024 and 16 January 2024)
- A summary of launch activities for FebriDx in the US and Europe and the commercial opportunities linked to recent distribution agreements, plus discussion of the recently published Spanish paediatric study (ASX: 8 April 2024)
- Discussion regarding the launch of and strong debut for ViraDx through the US 2023/24 flu season and
- Future potential revenue drivers

Investors are invited to access the video via the following link:

<https://lumosdiagnostics.com/news-detail/Quarterly-Interview-with-LDX-CEO-Doug-Ward>

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

For personal use only

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
H[^]CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
info@lumosdiagnostics.com
+61 3 9087 1598

For personal use only